NYSE:AMAM Ambrx Biopharma (AMAM) Stock Price, News & Analysis → Next President (Not Trump. Not Biden.) (From The Freeport Society) (Ad) Free AMAM Stock Alerts $28.00 0.00 (0.00%) (As of 03/7/2024) Add Compare Share Share Today's Range$28.00▼$28.0050-Day Range$27.70▼$28.0052-Week Range$6.55▼$28.15VolumeN/AAverage Volume2.12 million shsMarket Capitalization$1.77 billionP/E RatioN/ADividend YieldN/APrice Target$24.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get Ambrx Biopharma alerts: Email Address Ambrx Biopharma MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside13.8% Downside$24.13 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.45) to ($1.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.05 out of 5 starsMedical Sector909th out of 914 stocksBiological Products, Except Diagnostic Industry152nd out of 152 stocks 1.3 Analyst's Opinion Consensus RatingAmbrx Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageAmbrx Biopharma has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for AMAM. Previous Next 0.0 Dividend Strength Dividend YieldAmbrx Biopharma does not currently pay a dividend.Dividend GrowthAmbrx Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AMAM. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 5 people have searched for AMAM on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ambrx Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.64% of the stock of Ambrx Biopharma is held by insiders.Percentage Held by Institutions77.28% of the stock of Ambrx Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ambrx Biopharma are expected to grow in the coming year, from ($1.45) to ($1.28) per share.Price to Book Value per Share RatioAmbrx Biopharma has a P/B Ratio of 9.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyNext President (Not Trump. Not Biden.)Do you want to see who I believe will be the next president of the U.S.A? It won't be Biden… And it won't be Trump.Click here to see why it will be _______________. About Ambrx Biopharma Stock (NYSE:AMAM)Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.Read More AMAM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMAM Stock News HeadlinesApril 9, 2024 | americanbankingnews.comSolid Biosciences (NASDAQ:SLDB) and Ambrx Biopharma (NYSE:AMAM) Head to Head AnalysisApril 5, 2024 | benzinga.comLatest News for Johnson & Johnson Stock (NYSE:JNJ)April 18, 2024 | The Freeport Society (Ad)Next President (Not Trump. Not Biden.)Do you want to see who I believe will be the next president of the U.S.A? It won't be Biden… And it won't be Trump.March 7, 2024 | finanznachrichten.deAmbrx Biopharma Inc.: Ambrx Shareholders Approve Acquisition by Johnson & JohnsonMarch 7, 2024 | markets.businessinsider.comJohnson & Johnson Buys Ambrx Biopharma In $2 Bln Cash DealMarch 6, 2024 | globenewswire.comAmbrx Shareholders Approve Acquisition by Johnson & JohnsonFebruary 23, 2024 | investorplace.com3 Stocks to Buy That Are Up 200% or More in 2024February 20, 2024 | msn.comIs Ambrx Biopharma Inc. (AMAM) Stock Outpacing Its Medical Peers This Year?April 18, 2024 | The Freeport Society (Ad)Next President (Not Trump. Not Biden.)Do you want to see who I believe will be the next president of the U.S.A? It won't be Biden… And it won't be Trump.February 12, 2024 | stockhouse.comSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates DOOR, CBAY, WISH, AMAMFebruary 10, 2024 | businesswire.comAMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAMJanuary 20, 2024 | stockhouse.comSHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AXNX, AMAM, HARPJanuary 11, 2024 | msn.comJMP Securities Downgrades Ambrx Biopharma (AMAM)January 10, 2024 | realmoney.thestreet.comAmbrx Biopharma just downgraded at JMP Securities, here's whyJanuary 9, 2024 | finance.yahoo.comAmbrx (AMAM) Skyrockets 102% on $2B Buyout Offer From J&JJanuary 8, 2024 | nasdaq.comJ&J to buy cancer therapy developer Ambrx for $2 blnJanuary 8, 2024 | tmcnet.comAMAM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Ambrx Biopharma, Inc. Is Fair to ShareholdersJanuary 8, 2024 | markets.businessinsider.comCrude Oil Falls Sharply; Ambrx Biopharma Shares Spike HigherJanuary 8, 2024 | investorplace.comWhy Is Ambrx Biopharma (AMAM) Stock Up 100% Today?January 8, 2024 | reuters.comJohnson & Johnson to buy Ambrx Biopharma for $2 blnJanuary 8, 2024 | finance.yahoo.comAmbrx Announces Sale to Johnson & JohnsonDecember 14, 2023 | msn.comAmbrix to Join NASDAQ Biotech IndexDecember 14, 2023 | finance.yahoo.comAmbrx to be Added to the NASDAQ Biotechnology Index (NBI)November 29, 2023 | markets.businessinsider.comOptimistic Outlook on Ambrx Biopharma’s Pipeline Justifies Buy RatingNovember 28, 2023 | finance.yahoo.comAmbrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate CancerNovember 18, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Twist Bioscience (TWST) and Ambrx Biopharma (AMAM)November 14, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ambrx Biopharma (AMAM) and Viridian Therapeutics (VRDN)See More Headlines Receive AMAM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ambrx Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:AMAM CUSIPN/A CIK1836056 Webambrx.com Phone858-875-2400FaxN/AEmployees87Year FoundedN/APrice Target and Rating Average Stock Price Target$24.13 High Stock Price Target$32.00 Low Stock Price Target$9.00 Potential Upside/Downside-13.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio13.28 Quick Ratio13.28 Sales & Book Value Annual Sales$7.40 million Price / Sales238.95 Cash FlowN/A Price / Cash FlowN/A Book Value$3.05 per share Price / Book9.18Miscellaneous Outstanding Shares63,150,000Free Float62,746,000Market Cap$1.77 billion OptionableOptionable Beta-1.92 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Daniel J. O'Connor J.D. (Age 59)CEO, President & Director Comp: $509.94kMs. Sonja Nelson CPA (Age 51)Chief Financial Officer Comp: $1.18MMr. Andrew P. Aromando (Age 55)Chief Operating Officer Dr. Ying J. Buechler Ph.D.Chief Technology OfficerDr. Shawn Shao-Hui Zhang Ph.D.Chief Scientific Officer & GM of ChinaMr. Jared KellySenior VP, General Counsel & Corporate SecretaryMr. Robert AzzaraVice President of Human CapitalDr. Sandra Aung Ph.D.Chief Clinical OfficerMs. Renu Vaish M.Sc. (Age 57)Chief Regulatory Officer More ExecutivesKey CompetitorsRecursion PharmaceuticalsNASDAQ:RXRXNeumora TherapeuticsNASDAQ:NMRAFusion PharmaceuticalsNASDAQ:FUSNSana BiotechnologyNASDAQ:SANATwist BioscienceNASDAQ:TWSTView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 1,399,642 shares on 3/11/2024Ownership: 2.216%Perceptive Advisors LLCBought 78,811 shares on 2/26/2024Ownership: 0.125%Virtu Financial LLCBought 20,386 shares on 2/26/2024Ownership: 0.032%Sierra Summit Advisors LLCBought 37,237 shares on 2/22/2024Ownership: 0.059%Price T Rowe Associates Inc. MDBought 262,683 shares on 2/16/2024Ownership: 1.717%View All Insider TransactionsView All Institutional Transactions AMAM Stock Analysis - Frequently Asked Questions Should I buy or sell Ambrx Biopharma stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ambrx Biopharma in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AMAM shares. View AMAM analyst ratings or view top-rated stocks. What is Ambrx Biopharma's stock price target for 2024? 8 analysts have issued 1-year target prices for Ambrx Biopharma's stock. Their AMAM share price targets range from $9.00 to $32.00. On average, they anticipate the company's share price to reach $24.13 in the next twelve months. This suggests that the stock has a possible downside of 13.8%. View analysts price targets for AMAM or view top-rated stocks among Wall Street analysts. How have AMAM shares performed in 2024? Ambrx Biopharma's stock was trading at $14.24 at the beginning of 2024. Since then, AMAM stock has increased by 96.6% and is now trading at $28.00. View the best growth stocks for 2024 here. What ETFs hold Ambrx Biopharma's stock? ETFs with the largest weight of Ambrx Biopharma (NYSE:AMAM) stock in their portfolio include AltShares Merger Arbitrage ETF (ARB).Range Cancer Therapeutics ETF (CNCR). When did Ambrx Biopharma IPO? Ambrx Biopharma (AMAM) raised $126 million in an IPO on Friday, June 18th 2021. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, BofA Securities and Cowen served as the underwriters for the IPO. How do I buy shares of Ambrx Biopharma? Shares of AMAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:AMAM) was last updated on 4/18/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsNext President (Not Trump. Not Biden.)The Freeport SocietyThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTIForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressYour Money is Not SafeAmerican AlternativeThe Next Nvidia?InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ambrx Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.